[Unrelated or sibling donor allogeneic bone marrow transplantation for myelodysplastic syndrome].

OBJECTIVE

To study on allogeneic bone marrow transplantation (BMT) with unrelated donor or sibling donor for myelodysplastic syndrome-refractory anemia and myelodysplastic syndrome-refractory anemia with excess blasts in transformation patients.

METHODS

Two male patients received chemotherapy regimen of busulfan-cyclophosphamide before allogeneic BMT. Mycophenolate mofetil combined with cyclosporin A and methotrexate was used for prevention of acute graft-versus-host disease after transplantation. Low dose heparin and lipo prostaglandin E1 were used in prophylactic regimen for hepatic veno-occlusive disease.

RESULTS

Neutrophil count began to be higher than 0.5 x 10(9)/L on 21st and 17th days after BMT in the two patients. Disease-free survival in the two patients was 10 months and 3.5 months respectively.

CONCLUSION

Allogeneic bone marrow transplantation with unrelated or sibling donor is an effective therapy for patients with MDS.